• Neutrophil recovery at day +28 100 day survival (Stage I) [ Designated as safety issue: No ]
  
• Incidence of grade II-IV acute GVHD at day 100 (Stage II) [ Designated as safety issue: No ]
  

• Incidence of grade III-IV acute GVHD at day 100 [ Designated as safety issue: No ]
  
• Incidence of chronic GVHD at 6 months [ Designated as safety issue: No ]
  
• Relapse at 6 months [ Designated as safety issue: No ]
  
• Survival at 100 days and 1 year [ Designated as safety issue: No ]
  
• Comparison of other endpoints after transplant using KIR-ligand mismatched vs. matched donors [ Designated as safety issue: No ]
  
• Incidence of toxicity associated with the use of bortezomib [ Designated as safety issue: Yes ]
  

OBJECTIVES:

Primary

• To determine whether administration of donor NK Cells can permit engraftment and satisfactory 100 day survival after haploidentical hematopoietic stem cell transplantation (HSCT).

Secondary

• To determine the incidence of multiorgan toxicity, engraftment, acute and chronic GVHD, relapse, transplant-related (non-relapse) mortality and survival after transplantation.
• To compare these endpoints after transplantation using KIR-L matched vs. mismatched donors and in recipients missing 0, 1 or 2 KIR-L.
• To evaluate the safety of adding bortezomib (Velcade) to the preparative regimen.

OUTLINE: This is an open-label study.

Patients receive fludarabine IV over 1 hour daily on days -17 to -13, cyclophosphamide IV over 2 hours on day

• 13, and undergo total body irradiation on day -12. Patients then receive an infusion of donor natural killer cells on day -12 and receive interleukin-2 on alternating days on days -10 to -2 and undergo allogeneic peripheral blood stem cell transplantation on day 0. Patients also receive anti-thymocyte globulin IV over 4-6 hours on days 0-2.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study.